Li M - Search Results

1

Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.

Li M, Ding N, Mi L, Shi Y, Du X, Yi Y, Yang L, Liu W, Zhu J. Li M, et al. Leuk Lymphoma. 2022 Mar;63(3):608-617. doi: 10.1080/10428194.2021.1999441. Epub 2021 Nov 9. Leuk Lymphoma. 2022. PMID: 34751093

2

Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen.

Yu H, Mi L, Qi F, Wang X, Ye Y, Li M, Wang D, Ding N, Wang X, Song Y, Zhu J, Xie Y. Yu H, et al. Among authors: li m. Aging (Albany NY). 2022 Apr 10;14(7):3203-3215. doi: 10.18632/aging.204008. Epub 2022 Apr 10. Aging (Albany NY). 2022. PMID: 35400665 Free PMC article.

3

Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma.

Li M, Yu H, Qi F, Ye Y, Hu D, Cao J, Wang D, Mi L, Wang Z, Ding N, Ping L, Shu S, Zhu J. Li M, et al. Hematol Oncol. 2022 Oct;40(4):596-608. doi: 10.1002/hon.3009. Epub 2022 May 10. Hematol Oncol. 2022. PMID: 35477179

4

Ibrutinib combined with low-dose histone deacetylases inhibitor chidamide synergistically enhances the anti-tumor effect in B-cell lymphoma.

Yu H, Mi L, Zhang W, Ye Y, Li M, Hu D, Cao J, Wang D, Wang X, Ding N, Song Y, Zhu J. Yu H, et al. Among authors: li m. Hematol Oncol. 2022 Dec;40(5):894-905. doi: 10.1002/hon.3056. Epub 2022 Aug 24. Hematol Oncol. 2022. PMID: 35975476

5

Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era.

Nuersulitan R, Li M, Mi L, Wu M, Ji X, Liu Y, Zhao H, Wang G, Song Y, Zhu J, Liu W. Nuersulitan R, et al. Among authors: li m. Front Oncol. 2022 Aug 22;12:989258. doi: 10.3389/fonc.2022.989258. eCollection 2022. Front Oncol. 2022. PMID: 36072805 Free PMC article.

6

Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.

Li M, Mi L, Wang C, Wang X, Zhu J, Qi F, Yu H, Ye Y, Wang D, Cao J, Hu D, Yang Q, Zhao D, Ma T, Song Y, Zhu J. Li M, et al. BMC Med. 2022 Oct 25;20(1):369. doi: 10.1186/s12916-022-02562-3. BMC Med. 2022. PMID: 36280874 Free PMC article.

7

PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma.

Hu D, Cao J, Yu H, Ding N, Mi L, Ye Y, Li M, Wang D, Wu J, Wang X, Song Y, Zhu J, Ping L. Hu D, et al. Among authors: li m. Cancer Lett. 2024 Aug 10;597:216996. doi: 10.1016/j.canlet.2024.216996. Epub 2024 May 29. Cancer Lett. 2024. PMID: 38815797 Free article.

8

HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma.

Cheng H, Wang S, Huang A, Ma J, Gao D, Li M, Chen H, Guo K. Cheng H, et al. Among authors: li m. Cancer Biol Ther. 2023 Dec 31;24(1):1-9. doi: 10.1080/15384047.2022.2156242. Cancer Biol Ther. 2023. PMID: 36482717 Free PMC article.

9

HSF1: a mediator in metabolic alteration of hepatocellular carcinoma cells in cross-talking with tumor-associated macrophages.

Liu HT, Huang DA, Li MM, Liu HD, Guo K. Liu HT, et al. Am J Transl Res. 2019 Aug 15;11(8):5054-5064. eCollection 2019. Am J Transl Res. 2019. PMID: 31497221 Free PMC article.

10

Effects of LRP1B Regulated by HSF1 on Lipid Metabolism in Hepatocellular Carcinoma.

Li M, Hu J, Jin R, Cheng H, Chen H, Li L, Guo K. Li M, et al. Among authors: li l. J Hepatocell Carcinoma. 2020 Dec 8;7:361-376. doi: 10.2147/JHC.S279123. eCollection 2020. J Hepatocell Carcinoma. 2020. PMID: 33324588 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74,183 results

Search Page

Filters